Research
Research

Alzheimer Drug Sabirnetug Fails Key Trial Goal

By Claire Ashworth ·

Cognitive Decline Persists Despite Amyloid Reduction

Acumen Pharmaceuticals announced that its experimental Alzheimer's drug sabirnetug missed the primary cognitive endpoint in a Phase 2 clinical trial. The study, named ALTITUDE-AD, enrolled patients with early-stage Alzheimer's disease. Despite successfully reducing amyloid levels in the brain, the drug failed to show a statistically significant improvement in memory and thinking skills. Acumen has decided to halt further development of the drug.

The trial results reveal a critical gap between biological change and clinical benefit. Researchers observed that while sabirnetug effectively lowered amyloid plaques, patients did not experience the expected cognitive gains. This suggests that simply clearing amyloid is not enough to stop or reverse cognitive decline. The company plans to keep some participants in an open-label extension to monitor long-term effects.

What Does This Mean for Alzheimer's Treatment?

The failure highlights the complexity of treating Alzheimer's disease. Many drugs have targeted amyloid with mixed results. Acumen's decision to stop development saves resources and allows the company to refocus on other pipeline candidates. The open-label extension will provide data on safety and potential delayed benefits.

Did sabirnetug reduce amyloid levels? Yes, the drug successfully lowered amyloid levels in the brain. However, this biological change did not translate into the required improvement in cognitive function.

Frequently Asked Questions

Why did Acumen stop developing the drug? Acumen halted development because the trial missed its primary endpoint. The company will continue an open-label extension for remaining participants.

What is the open-label extension? It is a follow-up phase where participants continue receiving the drug without a control group. This allows researchers to track safety and observe any late-stage cognitive effects.